P0600: Do GI Quant small bowel motility values correlate with reported MR enterography findings in Crohn's disease?ECCO'25Year: 2025
Authors: Macpherson, S.(1)*;Ballantyne, S.(2);Brownson, E.(3);Campbell, I.(4);Robertson, A.(3);Hall, M.(5);Menys, A.(6);Seenan, J.P.(4);MacDonald, J.(4);
(1)NHS Greater Glasgow and Clyde, Clinical Radiology Department- Queen Elizabeth Univeristy Hospital QEUH, Glasgow, United Kingdom;(2)NHS Greater Glasgow and Clyde, Clinical Radiology Department- QEUH, Glasgow, United Kingdom;(3)NHS Greater Glasgow and Clyde, Gastroenterology Department- Glasgow Royal infirmary, Glasgow, United Kingdom;(4)NHS Greater Glasgow and Clyde, Gastroenterology Department- QEUH, Glasgow, United Kingdom;(5)NHS Greater Glasgow and Clyde, Clinical Radiology- QEUH, Glasgow, United Kingdom;(6)University College London, Centre for Medical Imaging, London, United Kingdom;
1) Gollifer RM, Menys A, Plumb A, Mengoudi K, Puylaery C, Tielbeek JA et al. Automated versus subjective assessment of spatial and temporal MRI small bowel motility in Crohn's disease. Clin Radiol . 2019 Oct;74(10):814.e9-814.e19.
2) Menys A, Puylaery C, Tutein Nolthenius C, Plumb A, Makanyanga J, Tielbeek J et al.Quantified Terminal Ileal Motility during MR Enterography as a Biomarker of Crohn Disease Activity: Prospective Multi-Institution Study 2018 Nov;289(2):428-435. doi: 10.1148/radiol.2018180100.
P0601: Is advanced combination therapy effective in patients with refractory Inflammatory Bowel Disease?ECCO'25Year: 2025
Authors: Rodríguez Gallardo, M.(1)*;Valdés Delgado, T.(1);Maldonado Pérez, B.(1);Belvis Jiménez, M.(1);Aguado Paredes, A.(2);Castro Laria, L.(1);Argüelles Arias, F.(3);
(1)Virgen Macarena University Hospital, Gastroenterology Department, Seville, Spain;(2)Virgen Macarena University Hospital, Pharmacology Department, Seville, Spain;(3)University of Seville-Virgen Macarena University Hospital, Gastroenterology Department, Seville, Spain;
P0602: Long-term effectiveness and safety of ustekinumab dose escalation in patients with refractory ulcerative colitis: a multicenter retrospective cohort studyECCO'25Year: 2025
Authors: Van Lierop, L.(1)*;Albino, L.(1);Rosentreter, R.(2);Thomas, P.W.A.(3);Lu, C.(4);Siffledeen, J.(1);Kroeker, K.I.(1);Ma, C.(4);Peerani, F.(1);Halloran, B.P.(1);Baumgart, D.C.(1);Dieleman, L.A.(1);Du, L.(1);Hoentjen, F.(1);Wong, K.(1);
(1)University of Alberta, Division of Gastroenterology, Edmonton, Canada;(2)University of Calgary, Division of Gastroenterolgoy, Calgary, Canada;(3)Radboud University Medical Center, Department of Gastroenterology, Nijmegen, The Netherlands;(4)University of Calgary, Division of Gastroenterology, Calgary, Canada;
P0603: The real-world use of intravenous and subcutaneous Vedolizumab in IBD across Australia and New Zealand, Crohn’s Colitis Cure Data Insight’s Program.ECCO'25Year: 2025
Authors: Su, W.K.(1,2,3);Wilson, W.(4);Wark, G.(5);Ghaly, S.(6,7);Lynch, K.(8,9);Lawrance, I.(10,11);Walker, G.(12,13,14);Forbes, A.(15);Brett, L.(16);An, Y.K.(17,18);Connor, S.J.(3,5,19)*;Andrews, J.M.(3,8,9);
(1)Liverpool Hospital, Department of Gastroenterology and Hepatology, Liverpool, Australia;(2)The Ingham Institute for Applied Medical Research, Gastroenterology and Hepatology, Liverpool, Australia;(3)Crohn's Colitis Cure, CCCure, Sydney, Australia;(4)Lyell McEwin Hospital, Department of Anaesthesia, Adelaide, Australia;(5)Liverpool Hospital, Department of Gastroenterology and Hepatology, Sydney, Australia;(6)St Vincent's Public Hospital, Department of Gastroenterology and Hepatology, Sydney, Australia;(7)University of New South Wales, St Vincent's Clinical School, Sydney, Australia;(8)Royal Adelaide Hospital, Department of Gastroenterology and Hepatology, Adelaide, Australia;(9)University of Adelaide, Faculty of Health Sciences, Adelaide, Australia;(10)Saint John of God Subiaco Hospital, Centre for Inflammatory Bowel Disease, Subiaco, Australia;(11)University of Western Australia, School of Medicine and Pharmacology, Murdoch, Australia;(12)Royal Brisbane and Women's Hospital-, Department of Gastroenterology and Hepatology, Brisbane, Australia;(13)QIMR Berghofer-, Gut Health, Brisbane, Australia;(14)University of Queensland-, Faculty of Medicine, Brisbane, Australia;(15)University of Otago, Department of Medicine, Christchurch, New Zealand;(16)Logan Hospital, Department of Gastroenterology, Brisbane, Australia;(17)Mater Hospital Brisbane, Department of Gastroenterology and Hepatology, Brisbane, Australia;(18)The University of Queensland, Mater Research- Faculty of Medicine, Brisbane, Australia;(19)University of New South Wales, Medicine & Health- South Western Sydney Clinical School-, Sydney, Australia;
P0604: Frequency and Analysis of Deep Remission in Patients with Ulcerative Colitis: A Single-Center Retrospective StudyECCO'25Year: 2025
Authors: Philippe Ponce, M.(1)*;Guinea Lagunes , A.(1);Contreras Aviles, E.(1);Almeida del Prado, G.(1);López Perez, R.(1);Villanueva Herrero, J.(1);Jiménez Bobadilla, B.(2);Sebastian Ocampo , V.(1);De Leon Rendon, J.L.(3);
(1)Coloproctology Service of Hospital General de México ´´Dr. Eduardo Liceaga´´, Inflammatory Bowel Disease Clinic, Ciudad de México, Mexico;(2)Coloproctology Service of Hospital General de México ´´Dr. Eduardo Liceaga´´, Coloproctology Service, Ciudad de México, Mexico;(3)Coloproctology Service of Hospital General de Méxco ´´Dr. Eduardo Liceaga´´, Clínica de Enfermedad Inflamatoria Intestinal, Ciudad de México, Mexico;
1. Sands BE, Peyrin-Biroulet L, Loftus EV, Danese S, Colombel JF, Török HP, et al. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. N Engl J Med. 2019;381(13):1215–26. 2. Turner D, Ricciuto A, Lewis A, D’Amico F, Dhaliwal J, Griffiths AM, et al. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (IBD) Consensus Guidelines from the International Organization for the Study of IBD (IOIBD). J Crohns Colitis. 2021;15(6):881–93. 3. Dignass A, Eliakim R, Magro F, Maaser C, Chowers Y, Geboes K, et al. Second European Evidence-Based Consensus on the Diagnosis and Management of Ulcerative Colitis Part 2: Current Management. J Crohns Colitis. 2012;6(10):991–1030. 4. Dulai PS, Singh S, Casteele NV, Boland BS, Jairath V, Feagan BG, et al. Development and Validation of a Novel Clinical Scoring Tool to Predict Outcomes with Biological Therapy in Patients with Ulcerative Colitis. Aliment Pharmacol Ther. 2018;47(5):714–22. 5. Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG Clinical Guideline: Management of Crohn's Disease in Adults. Am J Gastroenterol. 2018;113(4):481–517. 6. Harbord M, Eliakim R, Bettenworth D, Karmiris K, Katsanos KH, Kopylov U, et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. J Crohns Colitis. 2017;11(7):769–84. 7. Colombel JF, Narula N, Peyrin-Biroulet L. Management Strategies to Improve Outcomes of Patients with Inflammatory Bowel Diseases. Gastroenterology. 2017;152(2):351–61. 8. Hanauer SB, Sandborn WJ, Lichtenstein GR, Rubin DT. The Management of Ulcerative Colitis: Current Treatment Approaches. Clin Gastroenterol Hepatol (2005).
P0605: Nutritional Therapy for IBD: a new non-profit organization that offers trusted, evidence-based information and novel resources on diet and nutritional therapies in IBDECCO'25Year: 2025
Authors: Prados, A.(1,2)*;Sigall-Boneh, R.(3,4);Gold, S.(5);Haskey, N.(6);Day, A.(7);Beall, K.(1);
(1)Nutritional Therapy for IBD, Nutritional Therapy for IBD, Mount Pleasant, United States;(2)Universitat Ramon Llull, Blanquerna School of Health Science, Barcelona, Spain;(3)The E. Wolfson Medical Center, Pediatric Gastroenterology and Nutrition Unit, Holon, Israel;(4)University of Amsterdam, Tytgat Institute for Liver and Intestinal Research- Amsterdam Gastroenterology Endocrinology and Metabolism, Amsterdam, The Netherlands;(5)Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States;(6)University of British Columbia-Okanagan, Department of Biology, Kelowna- BC, Canada;(7)University of Otago, Department of Paediatrics, Christchurch, New Zealand; On behalf of the Medical Advisory Board of Nutritional Therapy for IBD.
1.Fusco, S., Briese, K., Keller, R., et al. (2024). Are Internet information sources helpful for adult Crohn’s disease patients regarding nutritional advice? J Clin Med, 13(10), 2834. https://doi.org/10.3390/jcm13102834
2.Gkikas, K., Wan, M., Svolos, V., et al. (2024). YouTube as a source of information for food, diet-related items, and advisory comments for the management of inflammatory bowel disease. Inflamm Bowel Dis, 30(3), 347-356. https://doi.org/10.1093/ibd/izad076
P0607: Opportunistic infections in patients with inflammatory bowel disease under advanced drug therapy. Real-word experience of 8 years from a medium-volume center in Cordoba, Argentina.ECCO'25Year: 2025
Authors: Torello, R.(1);Salvatierra, M.(1);Balderramo, D.C.(2)*;
(1)Hospital Privado Universitario de Cordoba, Gastroenterology, Cordoba, Argentina;(2)Hospital Privado Universitario de Cordoba, IBD section, Cordoba, Argentina;
Balderramo D, Quaresma AB, Olivera PA, Savio MC, Villamil MPG, Panaccione R, Ng SC, Kaplan GG, Kotze PG. Challenges in the diagnosis and treatment of inflammatory bowel disease in Latin America. Lancet Gastroenterol Hepatol. 2024 Mar;9(3):263-272. doi: 10.1016/S2468-1253(23)00284-4. PMID: 38340754.
P0608: Safety of guselkumab in Inflammatory Bowel Disease up to 1 year: Integrated safety analysis of phase 2 and 3 studies in Crohn’s Disease and Ulcerative ColitisECCO'25Year: 2025
Authors: Sands, B.E.(1)*;Panaccione, R.(2);Danese, S.(3);Panés, J.(4);Hisamatsu, T.(5);D’Haens, G.(6);Van Rampelbergh, R.(7);Olurinde, M.(8);Yee, J.(8);Baker, T.(8);Yarandi, S.(8);Germinaro, M.(8);Vetter, M.L.(8);Li, H.(8);Rosas Ballina, M.(9);Allegretti, J.(10);Afzali, A.(11);Rubin, D.T.(12);
(1)Ichan School of Medicine at Mt. Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York, United States;(2)University of Calgary, Inflammatory Bowel Disease Unit- Division of Gastroenterology, Calgary, Canada;(3)IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Gastroenterology and Endoscopy, Milano, Italy;(4)Hospital Clínic de Barcelona, IDIBAPS- CIBERehd, Barcelona, Spain;(5)Kyorin University School of Medicine, Department of Gastroenterology and Hepatology, Tokyo, Japan;(6)Amsterdam University Medical Centers, Department of Gastroenterology, Amsterdam, The Netherlands;(7)Janssen Research & Development, Immunology, Antwerp, Belgium;(8)Janssen Research & Development, Immunology, Spring House, United States;(9)Actelion Research & Development, Immunology, Allschwil, Switzerland;(10)Brigham and Women's Hospital and Harvard Medical School, Division on Gastroenterology- Hepatology- and endoscopy, Boston, United States;(11)University of Cincinnati, College of Medicine, Cincinnati, United States;(12)University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, United States;
P0609: Real-world short and long-term effectiveness of risankizumab in refractory Crohn’s disease: RISANCROHN study from the ENEIDA RegistryECCO'25Year: 2025
Authors: Barreiro-de Acosta, M.(1)*;Nieto-Garcia, L.(1);Poncela, M.(2);Aguas, M.(3);Martinez Cuevas, C.(4);Argüelles-Arias, F.(5);Calvo, M.(6);Gargallo-Puyuelo, C.J.(7);Zabalza, L.(8);Varela Trastoy, P.(9);Bosca-Watts, M.M.(10);Ceballos, D.(11);Martinez-Pascual, C.(12);Rodríguez-Moranta, F.(13);de Castro Parga, M.L.(14);Suárez, P.(15);Camps, B.(16);Royo, V.(17);Bastón-Rey, I.(1);de Francisco , R.(18);Garcia-Lopez, S.(19);Martín-Arranz, M.D.(20);Alonso-Abreu, I.(21);Gisbert, J.P.(22);Rivero, M.(23);Sicilia, B.(24);Nicolás, I.(25);Teller, M.(26);Ponferrada, Á.(27);Ricart, E.(28);Algara, M.(29);Fradejas, P.(30);Robledo, P.(31);Madero, L.(32);Elorza, A.(33);Piqueras, M.(34);Zabana, Y.(35);Porto-Silva, S.(1);Domènech, E.(36);Ferreiro-Iglesias, R.(1);
(1)University Hospital Santiago De Compostela CHUS, Department of Gastroenterology- IBD Unit, Santiago De Compostela, Spain;(2)Hospital General Universitario Gregorio Marañón- Instituto de Investigación Biomédica Gregorio Marañón IiSGM, Department of Gastroenterology, Madrid, Spain;(3)Hospital Universitari i Politecnic La Fe, Department of Gastroenterology, Valencia, Spain;(4)Hospital Universitario Rio Hortega, Department of Gastroenterology, Valladolid, Spain;(5)University of Sevilla.Hospital Universitario Virgen Macarena, Department of Gastroenterology, Sevilla, Spain;(6)Hospital Universitario Puerta de Hierro Majadahonda, Department of Gastroenterology, Madrid, Spain;(7)Hospital Clínico Universitario “Lozano Blesa”- IIS Aragón and CIBERehd, Department of Gastroenterology, Zaragoza, Spain;(8)Hospital Universitario de Navarra, Department of Gastroenterology, Pamplona, Spain;(9)Hospital de Cabueñes, Department of Gastroenterology, Gijón, Spain;(10)Hospital Clínico Universitario de Valencia-Universitat de València, Department of Gastroenterology, Valencia, Spain;(11)Hospital Universitario de Gran Canaria Dr. Negrín, Department of Gastroenterology, Las Palmas, Spain;(12)H.C.U.Virgen de la Arrixaca, Department of Gastroenterology, Murcia, Spain;(13)Hospital Universitario de Bellvitge- IDIBELL, Department of Gastroenterology, L'Hospitalet de Llobregat- Barcelona, Spain;(14)Hospital Álvaro Cunqueiro- Estrutura Organizativa de Xestión Integrada de Vigo, Department of Gastroenterology, Vigo, Spain;(15)Complejo Asistencial Universitario León, Department of Gastroenterology-, Leon, Spain;(16)Hospital del Mar- IMIM Hospital del Mar Medical Research Institute, Department of Gastroenterology, Barcelona, Spain;(17)Hospital Son Espases, Department of Gastroenterology, Palma de Mallorca, Spain;(18)Hospital Universitario Central de Asturias and ISPA, Department of Gastroenterology, Oviedo, Spain;(19)Hospital Universitario Miguel Servet, Department of Gastroenterology, Zaragoza, Spain;(20)School of Medicine. Universidad Autónoma de Madrid. Hospital La Paz Institute for Health Research- La Paz Hospital, Department of Gastroenterology, Madrid, Spain;(21)Hospital Universitario de Canarias H.U.C., Department of Gastroenterology, Santa Cruz de Tenerife, Spain;(22)Instituto de Investigación Sanitaria Princesa IIS-Princesa- Universidad Autónoma de Madrid UAM- and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBERehd, Department of Gastroenterology, Madrid, Spain;(23)Hospital Universitario Marqués de Valdecilla and IDIVAL, Department of Gastroenterology, Santander, Spain;(24)Hospital Universitario de Burgos, Department of Gastroenterology, Santiago De Compostela, Spain;(25)Hospital General Universitario Reina Sofía, Department of Gastroenterology, Murcia, Spain;(26)Althaia Xarxa Assistencial universitaria de Manresa, Department of Gastroenterology, Manresa, Spain;(27)Hospital Universitario Infanta Leonor, Department of Gastroenterology, Madrid, Spain;(28)Hospital Clínic i Provincial- Institut d'Investigacions Biomèdiques August Pi i Sunyer, Department of Gastroenterology, Barcelona, Spain;(29)Hospital Universitario 12 de Octubre, Department of Gastroenterology, Madrid, Spain;(30)Complejo Asistencial de Zamora, Department of Gastroenterology, Zamora, Spain;(31)Hospital Universitario de Cáceres, Department of Gastroenterology, Cáceres, Spain;(32)Hospital General Universitario de Alicante and CIBERehd, Department of Gastroenterology, Alicante, Spain;(33)Hospital de Galdakao-Usansolo, Department of Gastroenterology, Galdakao, Spain;(34)Consorci Sanitari Terrasa, Department of Gastroenterology, Terrasa, Spain;(35)Hospital Universitari Mutua Terrasa and CIBEREHD, Department of Gastroenterology, Terrasa, Spain;(36)Hospital Universitari Germans Trias I Pujol and CIBEREHD, Department of Gastroenterology-, Badalona, Spain;
P0610: Comparison of endoscopic remission and MRI defined remission using the simplified MaRIA score at week 48 from the PROFILE trialECCO'25Year: 2025
Authors: Bhandari, M.(1)*;Noor, N.(2);Paverd, H.(3);De Paepe, K.(4);Godfrey, E.(3);Hickman, K.(3);Khwaja, S.(3);Lee, J.(5);Raine, T.(1);Kennedy, N.(6);Upponi, S.(3);Parkes, M.(7);
(1)Cambridge University Hospitals NHS Foundation Trust, Department of Gastroenterology-, Cambridge, United Kingdom;(2)Cambridge University Hospitals NHS Foundation Trust-, Department of Gastroenterology, Cambridge- UK, United Kingdom;(3)Cambridge University Hospitals NHS Foundation Trust, Department of Radiology, Cambridge, United Kingdom;(4)Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, United Kingdom;(5)The Francis Crick Institute, Genetic Mechanisms of Disease Laboratory, London, United Kingdom;(6)Royal Devon University Healthcare NHS Foundation Trust, Department of Gastroenterology, Exeter, United Kingdom;(7)Cambridge University Hospitals NHS Foundation Trust, Department of Gastroenterology, Cambridge, United Kingdom; PROFILE study group
[1] Noor NM, Lee JC, Bond S, Dowling F, Brezina B, Patel KV, Ahmad T, Banim PJ, Berrill JW, Cooney R, De La Revilla Negro J, de Silva S, Din S, Durai D, Gordon JN, Irving PM, Johnson M, Kent AJ, Kok KB, Moran GW, Mowat C, Patel P, Probert CS, Raine T, Saich R, Seward A, Sharpstone D, Smith MA, Subramanian S, Upponi SS, Wiles A, Williams HRT, van den Brink GR, Vermeire S, Jairath V, D'Haens GR, McKinney EF, Lyons PA, Lindsay JO, Kennedy NA, Smith KGC, Parkes M; PROFILE Study Group. A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial. Lancet Gastroenterol Hepatol. 2024 May;9(5):415-427. doi: 10.1016/S2468-1253(24)00034-7. Epub 2024 Feb 22. PMID: 38402895; PMCID: PMC11001594.
[2] Yzet C, Diouf M, Le Mouel JP, Brazier F, Turpin J, Loreau J, Dupas JL, Peyrin-Biroulet L, Fumery M. Complete Endoscopic Healing Associated With Better Outcomes Than Partial Endoscopic Healing in Patients With Crohn's Disease. Clin Gastroenterol Hepatol. 2020 Sep;18(10):2256-2261. doi: 10.1016/j.cgh.2019.11.025. Epub 2019 Nov 16. PMID: 31743755.
P0611: Effectiveness comparisons between tofacitinib, filgotinib and upadacitinib in ulcerative colitis: results from the JAKARTA real-world evidence multicenter studyECCO'25Year: 2025
Authors: Buisson, A.(1)*;Treton, X.(2);Nachury, M.(3);Uzzan, M.(4);Bouguen, G.(5);Banana Hamadidi, A.(1);Amiot, A.(6);Serrero, M.(7);Fumery, M.(8);Caillo, L.(9);Hupé, M.(10);Pereira, B.(1);Altwegg, R.(11);
(1)CHU Clermont-Ferrand, IBD Unit, Clermont-Ferrand, France;(2)Paris IBD Center, IBD Unit, Paris, France;(3)CHRU Lille, IBD Unit, Lille, France;(4)CHU Créteil, IBD Unit, Créteil, France;(5)CHU Rennes, IBD Unit, Rennes, France;(6)AP-HP Kremlin-Bicêtre, IBD Unit, Paris, France;(7)AP-HM, IB Unit, Marseille, France;(8)CHU Amiens, IBD Unit, Amiens, France;(9)CHU Nîmes, IBD Unit, Nîmes, France;(10)CHU Grenoble, IBD Unit, Grenoble, France;(11)CHU Montpellier, IBD Unit, Montpellier, France;
P0612: Postoperative outcomes in tofacitinib-treated patients with acute severe ulcerative colitis undergoing total abdominal colectomyECCO'25Year: 2025
Authors: Larson, C.(1);Berinstein, J.A.(1,2);Tedesco, N.(1,2);Seidelin, J.B.(3);Ovesen, P.D.(3);Uzzan, M.(4);Amiot, A.(5);Nuzzo, A.(6);Laharie, D.(7);Constant, B.D.(8,9);Albenberg, L.(9);El-Hussuna, A.(10);Bishu, S.(1);,2;Cohen-Mekelburg, S.(1);,2;Higgins, P.D.R.(1,2);Steenholdt, C.(11,12)*;
(1)University of Michigan, Department of Internal Medicine, Ann Arbor, United States;(2)University of Michigan, Department of Gastroenterology and Hepatology, Ann Arbor, United States;(3)Rigshospitalet, Department of Digestive Diseases- Transplantation and General Surgery, Copenhagen, Denmark;(4)Paris Est Créteil University UPEC- Assistance Publique-Hôpitaux de Paris AP-HP- Henri Mondor Hospital- Fédération Hospitalo-Universitaire, Innovative therapy for immune disorders TRUE- Gastroenterology Department-, Paris, France;(5)Henri Mondor University Hospital, Department of Gastroenterology, Creteil, France;(6)Beaujon Hospital APHP- Université de Paris, Department of Gastroenterology- IBD- and Nutritional Support, Paris, France;(7)CHU de Bordeaux- Centre Medico-chirurgical Magellan- Hôpital Haut-Lévêque- Université de Bordeaux, Gastroenterology department, Bordeaux, France;(8)University of Colorado School of Medicine- Digestive Health Institute- Children's Hospital Colorado, Department of Pediatrics, Aurora, United States;(9)The Children's Hospital of Philadelphia, Division of Gastroenterology- Hepatology- and Nutrition, Philadelphia, United States;(10)OpenSourceResearch organization, OpenSourceResearch organization, Aalborg, Denmark;(11)Herlev Hospital, Dept of Gastroenterology, Herlev, Denmark;(12)Odense University Hospital, Department of Medical Gastroenterology, Odense, Denmark;
1. Steenholdt C, Dige Ovesen P, Brynskov J, et al. Tofacitinib for Acute Severe Ulcerative Colitis: A Systematic Review. J Crohns Colitis 2023;17:1354-1363.
2. Singh A, Goyal MK, Midha V, et al. Tofacitinib in Acute Severe Ulcerative Colitis (TACOS): A Randomized Controlled Trial. Am J Gastroenterol 2024;119:1365-1372.
P0613: Obesity is associated with inferior treatment outcomes in inflammatory bowel disease: a nationwide Dutch registry studyECCO'25Year: 2025
Authors: Oomkens, D.(1)*;Mujagic, Z.(2);de Vries, A.(3);van der Meulen-de Jong, A.(4);Straatmijer, T.(4);Löwenberg, M.(5);van der Marel, S.(6);West, R.(7);Bodelier, A.(8);van Schaik, F.(9);Visschedijk, M.(10);Duijvestein, M.(1);
(1)Radboud University Medical Centre, Gastroenterology and Hepatology, Nijmegen, The Netherlands;(2)Maastricht Universtiy Medical Centre, Gastroenterology and Hepatology, Maastricht, The Netherlands;(3)Erasmus Medical Centre, Gastroenterology and Hepatology, Rotterdam, The Netherlands;(4)Leiden University Medical Centre, Gastroenterology and Hepatology, Leiden, The Netherlands;(5)Amsterdam University Medical Centre, Gastroenterology and Hepatology, Amsterdam, The Netherlands;(6)Haaglanden Medical Centre, Gastroenterology and Hepatology, The Hague, The Netherlands;(7)Franciscus Gasthuis & Vlietland, Gastroenterology and Hepatology, Rotterdam, The Netherlands;(8)Amphia Hospital, Gastroenterology and Hepatology, Breda, The Netherlands;(9)University Medical Centre Utrecht, Gastroenterology and Hepatology, Utrecht, The Netherlands;(10)University Medical Centre Groningen, Gastroenterology and Hepatology, Groningen, The Netherlands; Initiative on Crohn and Colitis
P0614: Positive association of inflammatory bowel disease service research activity and adult patient-reported quality of care in the United KingdomECCO'25Year: 2025
Authors: Mulligan, R.(1)*;Brookes, M.J.(2);Ryan, P.(3);Turner, J.(4);Beck, L.(1);Selinger, C.P.(5);Hawthorne, A.B.(6);Lamb, C.A.(1);
(1)Newcastle University, Translational and Clinical Research Institute, Newcastle Upon Tyne, United Kingdom;(2)The Royal Wolverhampton NHS Trust, Department of Gastroenterology, Wolverhampton, United Kingdom;(3)NIHR Research Delivery Network RDN, West Midlands Regional Research Delivery Network, West Midlands, United Kingdom;(4)Crohn’s & Colitis UK, Crohn’s & Colitis UK, Hatfield, United Kingdom;(5)Leeds Teaching Hospitals NHS Trust, Department of Gastroenterology, Leeds, United Kingdom;(6)Cardiff & Vale University Health Board, Department of Gastroenterology, Cardiff, United Kingdom; IBD UK Board
1. Downing A, Morris EJ, Corrigan N, et al. High hospital research participation and improved colorectal cancer survival outcomes: a population-based study. Gut. 2017;66(1):89-96. doi:10.1136/gutjnl-2015-311308
2. Ozdemir BA, Karthikesalingam A, Sinha S, et al. Research activity and the association with mortality. PLoS One. 2015;10(2):e0118253. Published 2015 Feb 26. doi:10.1371/journal.pone.0118253
3. Jonker L, Fisher SJ, Dagnan D. Patients admitted to more research-active hospitals have more confidence in staff and are better informed about their condition and medication: Results from a retrospective cross-sectional study. J Eval Clin Pract. 2020;26(1):203-208. doi:10.1111/jep.13118
P0615: Effectiveness and Safety Analysis of Upadacitinib in the Treatment of Inflammatory Bowel Disease: A Multicenter Real-World StudyECCO'25Year: 2025
Authors: Wu, H.(1);Su, T.(1);Wu, L.(1);Zhi, M.(1);Yao, J.(1)*;
(1)Sun Yat-sen University Sixth Affiliated Hospital, Department of Gastroenterology, Guangzhou, China;
1.Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011;474(7351):307-317.
2.Ma C, Battat R, Dulai PS, et al. Innovations in Oral Therapies for Inflammatory Bowel Disease. Drugs. 2019;79(12):1321-1335.
3.Dunleavy KA, Pardi DS. Biologics: how far can they go in Crohn's disease? Gastroenterol Rep (Oxf). 2022;10:goac049.
4.Danese S, Argollo M, Le Berre C, Peyrin-Biroulet L. JAK selectivity for inflammatory bowel disease treatment: does it clinically matter? Gut. 2019;68(10):1893-1899.
5.Sandborn WJ, Feagan BG, Loftus EV, Jr., et al. Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease. Gastroenterology. 2020;158(8):2123-2138 e2128.
6.Sandborn WJ, Ghosh S, Panes J, et al. Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis. Gastroenterology. 2020;158(8):2139-2149 e2114.
7.HCP R. Dosing & Monitoring | Crohn's Disease. 2023; https://www.rinvoqhcp.com/crohns-disease/dosing-and-monitoring.
8.HCP R. Ulcerative Colitis Treatment Information. 2023; https://www.rinvoqhcp.com/ulcerative-colitis. Accessed 2024/4/12.
9.Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology. 2021;160(5):1570-1583.
P0617: Feasibility and safety of endoscopic submucosal dissection in inflammatory bowel disease (ESDEUR-IBD): an interim analysis of European retrospective studyECCO'25Year: 2025
Authors: García, M.J.(1)*;Fraile, M.(1);Katinios, G.(2);Gubbiotti, A.(3,4);Argyriou, K.(5);González-Partida, I.(6);Gavric, A.(7,8);de-Castro, M.L.(9);Fousekis, F.(10);Cudero Quintana, L.(11);Suchanek, S.(12,13);Caron, B.(14);Arranz, L.(15);López-García, A.(16);Ceballos, D.(17);Loly, J.P.(18);de María Pallares, P.(19);Bednarska, O.(2);Savarino, E.(3);Skamnelos, A.(10);Schaefer, M.(14);García Romero, D.(15);Rodríguez Pérez, C.(17);Suárez-Ferrer, C.(19);Terán, Á.(1);Rivero, M.(1);
(1)Hospital Universitario Marqués de Valdecilla- IDIVAL, Gastroenterology and Hepatology Department, Santander, Spain;(2)University Hospital in Linköping, Department of Gastroenterology and Hepatology, Linköping, Sweden;(3)University of Padua, Department of Surgery- Oncology and Gastroenterology, Padua, Italy;(4)Azienda Ospedale Università Padova, Gastroenterology Unit, Padua, Italy;(5)University Hospital of Larissa, IBD Unit- Department of Gastroenterology, Larissa, Greece;(6)Hospital Universitario Puerta de Hierro, Gastroenterology Department, Majadahonda- Madrid, Spain;(7)University Medical Centre Ljubljana, Department of Gastroenterology, Ljubljana, Slovenia;(8)Ljubljana Digestive Endoscopy Research Group, LuDERG, Ljubljana, Slovenia;(9)Complexo Hospitalario Universitario de Vigo CHUVI- Sergas- Grupo de Investigación en Patología Digestiva- Instituto de Investigación Sanitaria Galicia Sur IIS Galicia, Servicio de Aparato Digestivo, Vigo, Spain;(10)University Hospital of Ioannina, Department of Gastroenterology, Ioannina, Greece;(11)Hospital Universitario 12 de Octubre, Gastroenterology Department, Madrid, Spain;(12)1st Faculty of Medicine- Charles University- Military University Hospital, Department of Medicine, Prague, Czech Republic;(13)1st Faculty of Medicine- Charles University- Military University Hospital, Department of Gastrointestinal Oncology, Prague, Czech Republic;(14)Université de Lorraine- CHRU- Inserm- INFINY Institute- NGERE- F-54000, Gastroenterology Department, Nancy, France;(15)Hospital Universitario Nuestra Señora de Candelaria, Servicio de Digestivo, Santa Cruz de Tenerife, Spain;(16)Hospital Universitario Infanta Sofía, Gastroenterology Department, Madrid, Spain;(17)Hospital Universitario de Gran Canaria Dr. Negrín, Gastroenterology Department, Gran Canaria, Spain;(18)CHU Liège, Gastroenterology Department, Liège, Belgium;(19)Hospital Universitario La Paz, Gastroenterology Department, Madrid, Spain;
P0618: A Network Meta-analysis to Compare the Efficacy of Advanced Treatments for Biological-Experienced Patients with Ulcerative ColitisECCO'25Year: 2025
Authors: Kulkarni, A.(1)*;Giri , S.(2);Joshi , H.(3);
(1)Deenanath Mangeshkar Hopsital, Gastroenterology, Pune, India;(2)Kalinga Institute of Medical Sciences, Gastroenterology, Bhubaneshwar, India;(3)Nanavati Max Hospital, Gastroenterology, Mumbai, India;
P0619: Comparative efficacy of all available pharmaceutical therapies for moderate to severe Crohn’s disease: a systematic review and network meta-analysis.ECCO'25Year: 2025
Authors: Versteegh, M.(1)*;Idema, D.(2);Huygens, S.(1);Jenniskens, K.(2);Pierik, M.(3);Römkens, T.(4);van Schaik, F.(5);Wahab, P.(6);Huis in 't veld, L.(2);Kusters, M.(7);van der Braak, K.(2);Hooft, L.(2);Damen, J.(2);
(1)Dutch Health Care Institute, Research and development, Diemen, The Netherlands;(2)University Medical Center Utrecht, Cochrane Netherlands- Julius Center for Health Sciences and Primary Care, Utrecht, The Netherlands;(3)Medical University Medical Centre, Department of Gastroenterology-Hepatology, Maastricht, The Netherlands;(4)Jeroen Bosch Hospital, Department of Gastroenterology, 's Hertogenbosch, The Netherlands;(5)University Medical Centre, Department of Gastroenterology and Hepatology, Utrecht, The Netherlands;(6)Rijnstate Hospital, Department of Gastroenterology, Arnhem, The Netherlands;(7)University Medical Centre Utrecht, Cochrane Netherlands- Julius Center for Health Sciences and Primary Care, Utrecht, The Netherlands;
